What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence.
bone metastases
breast cancer
clinical trials
interleukins
preclinical studies
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Dec 2019
13 Dec 2019
Historique:
received:
27
11
2019
accepted:
07
12
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
19
12
2019
Statut:
epublish
Résumé
Breast cancer cells produce stimulators of bone resorption known as interleukins (ILs). However, data on the functional roles of ILs in the homing of metastatic breast cancer to bone are still fragmented. A systematic search was carried out in three databases (PubMed, Scopus, Web of Science Core Collection) to identify preclinical reports, and in three clinical registers (ClinicalTrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform, European Union (EU) Clinical Trials Register) to identify clinical trials, from 2008 to 2019. Sixty-seven preclinical studies and 11 clinical trials were recognized as eligible. Although preclinical studies identified specific key ILs which promote breast cancer bone metastases, which have pro-metastatic effects (e.g., IL-6, IL-8, IL-1β, IL-11), and whose inhibition also shows potential preclinical therapeutic effects, the clinical trials focused principally on ILs (IL-2 and IL-12), which have an anti-metastatic effect and a potential to generate a localized and systemic antitumor response. However, these clinical trials are yet to post any results or conclusions. This inconsistency indicates that further studies are necessary to further develop the understanding of cellular and molecular relations, as well as signaling pathways, both up- and downstream of ILs, which could represent a novel strategy to treat tumors that are resistant to standard care therapies for patients affected by breast cancer bone disease.
Identifiants
pubmed: 31847214
pii: cancers11122018
doi: 10.3390/cancers11122018
pmc: PMC6966526
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest regarding the publication of this article.
Références
Bone. 2015 Oct;79:176-82
pubmed: 26057367
J Cell Physiol. 2017 Jul;232(7):1826-1834
pubmed: 27925188
J Exp Med. 1993 Oct 1;178(4):1223-30
pubmed: 8104230
Mol Cancer. 2017 Sep 19;16(1):153
pubmed: 28927416
Anticancer Res. 2016 May;36(5):2227-32
pubmed: 27127127
Nat Commun. 2016 Feb 09;7:10442
pubmed: 26858125
Pain. 2018 Apr;159(4):684-698
pubmed: 29300279
Int J Mol Sci. 2016 Oct 04;17(10):
pubmed: 27782035
Cancer Res. 2008 Nov 1;68(21):9087-95
pubmed: 18974155
J Cell Physiol. 2011 Aug;226(8):2150-8
pubmed: 21520067
BMC Cancer. 2013 Jan 11;13:16
pubmed: 23311882
Cell Biochem Biophys. 2015 Jun;72(2):333-8
pubmed: 25543329
Breast Cancer Res Treat. 2013 Jan;137(2):631-6
pubmed: 23242617
Am J Pathol. 2007 Jan;170(1):160-75
pubmed: 17200191
Neoplasia. 2015 Dec;17(12):849-861
pubmed: 26696367
Bone. 2014 Sep;66:214-22
pubmed: 24956020
N Engl J Med. 2004 Apr 15;350(16):1655-64
pubmed: 15084698
Cell. 2014 Mar 27;157(1):267-71
pubmed: 24679541
Br J Cancer. 2013 Jun 25;108(12):2525-36
pubmed: 23801032
J Bone Miner Res. 2008 Jun;23(6):961-70
pubmed: 18435575
Mol Cancer. 2017 Feb 1;16(1):27
pubmed: 28143606
Crit Rev Oncol Hematol. 2005 Dec;56(3):365-78
pubmed: 15978828
Cancer Cell. 2011 Feb 15;19(2):192-205
pubmed: 21295524
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Clin Cancer Res. 2019 May 1;25(9):2769-2782
pubmed: 30670488
J Cell Biochem. 2010 Dec 1;111(5):1138-48
pubmed: 20683902
Sci Rep. 2017 May 11;7(1):1796
pubmed: 28496132
Nanotechnology. 2016 Jun 27;27(31):315103
pubmed: 27346678
Oncogene. 2012 Sep 13;31(37):4150-63
pubmed: 22158050
J Bone Oncol. 2017 Jan 28;6:16-21
pubmed: 28194325
Cell Rep. 2016 Jan 5;14(1):82-92
pubmed: 26725121
Breast Cancer. 2018 Sep;25(5):566-574
pubmed: 29557068
J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18
pubmed: 15615499
J Bone Oncol. 2016 Apr 13;5(3):124-127
pubmed: 27761372
Bone. 2014 Apr;61:176-85
pubmed: 24486955
Arthritis Res Ther. 2007;9 Suppl 1:S5
pubmed: 17634144
Cancer Biol Ther. 2011 Feb 1;11(3):311-6
pubmed: 21099351
PLoS One. 2013 Jul 18;8(7):e68171
pubmed: 23935856
Cell Death Dis. 2019 Apr 30;10(5):353
pubmed: 31040267
Med Oncol. 2013;30(3):634
pubmed: 23813018
Breast Cancer Res Treat. 2018 Sep;171(2):435-442
pubmed: 29808287
PLoS One. 2012;7(5):e37361
pubmed: 22629385
Mol Cancer. 2018 Jan 17;17(1):9
pubmed: 29343249
Cancer Biother Radiopharm. 2014 Apr;29(3):116-23
pubmed: 24392878
Acta Med Indones. 2016 Oct;48(4):261-268
pubmed: 28143986
Exp Cell Res. 2008 Jan 1;314(1):173-83
pubmed: 17976581
Cancer Res. 2010 Dec 15;70(24):10044-50
pubmed: 21159629
Cytokine. 2019 Jun;118:130-143
pubmed: 29625858
Cancer Invest. 2010 Nov;28(9):932-43
pubmed: 20690805
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
PLoS One. 2012;7(1):e29743
pubmed: 22235336
Nat Commun. 2016 Jul 13;7:12258
pubmed: 27406745
Oncol Res. 2009;18(4):173-84
pubmed: 20112503
J Natl Compr Canc Netw. 2009 Oct;7 Suppl 7:S1-29; quiz S30
pubmed: 19878635
Med Oncol. 2009;26(1):10-5
pubmed: 18461289
Clin Exp Metastasis. 2015 Oct;32(7):689-702
pubmed: 26231669
Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53
pubmed: 15807924
Oncotarget. 2016 Nov 15;7(46):75571-75584
pubmed: 27765923
J Cell Biochem. 2008 Jan 1;103(1):30-41
pubmed: 17471510
Korean J Physiol Pharmacol. 2018 Sep;22(5):503-511
pubmed: 30181697
Mol Cancer Res. 2011 Aug;9(8):1042-53
pubmed: 21700681
Sci Signal. 2016 Feb 02;9(413):ra12
pubmed: 26838548
Cell Death Dis. 2019 Jan 10;10(1):28
pubmed: 30631043
Spine Surg Relat Res. 2019 Apr 5;3(3):261-266
pubmed: 31440686
Tumour Biol. 2014 Jan;35(1):791-8
pubmed: 24026883
J Immunol. 2012 Feb 15;188(4):1981-91
pubmed: 22238453
Clin Cancer Res. 2006 Mar 1;12(5):1431-40
pubmed: 16533765
Clin Exp Metastasis. 2010 May;27(5):331-40
pubmed: 20446021
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Nat Rev Cancer. 2002 Aug;2(8):584-93
pubmed: 12154351
Mol Cancer Res. 2012 May;10(5):597-604
pubmed: 22522458
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Exp Metastasis. 2015 Apr;32(4):335-44
pubmed: 25749879
Breast Cancer Res. 2011 Oct 27;13(5):R106
pubmed: 22032690
Acta Biomater. 2015 Sep;24:333-42
pubmed: 26072364
Biochim Biophys Acta. 2015 Jan;1853(1):166-82
pubmed: 25409930
J Bone Miner Res. 2010 Jun;25(6):1295-304
pubmed: 20200931
J Bone Miner Res. 2014 Sep;29(9):1938-49
pubmed: 24676805
Clin Exp Metastasis. 2008;25(7):741-52
pubmed: 18543066
Endocr Relat Cancer. 2014 Mar 07;21(2):327-41
pubmed: 24413608
PLoS One. 2016 Feb 24;11(2):e0150151
pubmed: 26910109
Genes Cancer. 2012 Feb;3(2):117-30
pubmed: 23050044
Cancer Gene Ther. 2012 Sep;19(9):630-6
pubmed: 22744210
J Cell Physiol. 2014 Apr;229(4):453-62
pubmed: 24022654